Table 2.
Studies Investigating the Prognostic Value of Tumor Oxygenation in Head and Neck Cancer
| Study ID | N | pO2 (mmHg) median [Range] | Tx | Follow-up (months) median [range] | Findings | P-value |
|---|---|---|---|---|---|---|
| (A) Gatenby et al. (100) | 31 | NA [0–30] (Mean=13.6) | R | 3 [Not available] | Mean pO2 was 20.6±4.4 mmHg in the complete responders group and 4.7±3.0 mmHg in the nonresponders group. (Tumor volume 90 days after therapy) | <0.001 |
| (B) Nordsmark et al. (206) | 35 | 14 [1–35] | R | 17 [11–46] | 2-year LRC 33%↔HP2.5>15% 2-year LRC 77%↔HP2.5<15% |
0.01 |
| (C) Nordsmark and Overgaard (204) | 31 | 12 [0–54] | R | 28 [12–47] | 2-year LRC 45%↔HP2.5>15% 2-year LRC 90%↔HP2.5<15% |
0.04 |
| (D) Brizel et al. (21) | 63 | 5 [0–60] | R or R+C w/wo S | 20 [3–50] | 2-year LRC 73%↔median pO2>10 mmHg 2-year LRC 30%↔median pO2<10 mmHg |
0.01 |
| 2-year DFS 73%↔median pO2>10 mmHg 2-year DFS 26%↔median pO2<10 mmHg |
0.005 | |||||
| 2-year OS 83%↔median pO2>10 mmHg 2-year OS 35%↔median pO2<10 mmHg |
0.02 | |||||
| (E) Stadler et al. (251) | 59 | 13 [0–59] | R or R+C | 8 [<6–42] | Patients with HSV>6 ml have 2.5-shorter survival time than patients with HSV below this threshold. | 0.01 |
| (F) Rudat et al. (237) | 41 | 10 [0–62] (based on 60 pts) | R or R+C | 12 [2–37] | HP2.5 2.1 HR in univariate analysis | 0.05 |
| HP5 1.2 HR | 0.68 | |||||
| Median pO2 0.8 HR | 0.61 | |||||
| (G) Adam et al. (1) and Terris (262) | 25 | 20 [0–51] | R or R+C w/wo S | 16 [1–81] | No statistically significant correlation between HP2.5; HP5; HP10; Median pO2 and OS | |
| (H) Dietz et al. (67) | 37 | 3 [NA] | R or R+C | Not available | 3-year OS 14%↔median ΔpO2>0.8 mmHg 3-year OS 26%↔median ΔpO2<0.8 mmHg |
0.036 |
DFS, disease free survival; HR, hazard ratio; HSV, hypoxia subvolume; LRC, locoregional control; R, radiation; R+C, radiation plus chemotherapy; w/wo S, with or without surgery.